GALD — Galderma AG Share Price
Last trade - 00:00- CH₣21.37bn
- CH₣23.27bn
- $4.44bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 34.87 | ||
| PEG Ratio (f) | 0.71 | ||
| EPS Growth (f) | 96.67% | ||
| Dividend Yield (f) | 0.32% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.31 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 121.18 | ||
| Price to Sales | 5.81 | ||
| EV to EBITDA | 29.84 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.82% | ||
| Return on Equity | 3.51% | ||
| Operating Margin | 14.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 3,445 | 3,823.9 | 4,116.5 | 4,440 | 4,861.99 | 5,583.57 | 8.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +159.13 | +44.93 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 7th, 2022
- Public Since
- March 22nd, 2024
- No. of Employees
- 6,545
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 237,406,149
- Address
- Zaehlerweg 10, ZUG, 6300
- Web
- https://www.galderma.com/
- Phone
- Contact
- Emil Ivanov
- Auditors
- KPMG Audit Sarl
Latest News for GALD
Upcoming Events for GALD
Galderma Group AG at BNP Paribas Exane CEO Conference
Half Year 2025 Galderma Group AG Earnings Release
Q3 2025 Galderma Group AG Trading Statement Release
FAQ
As of Today at 20:45 UTC, shares in Galderma AG are trading at CH₣90.00. This share price information is delayed by 15 minutes.
Shares in Galderma AG last closed at CH₣90.00 and the price had moved by +38.52% over the past 365 days. In terms of relative price strength the Galderma AG share price has outperformed the FTSE Global All Cap Index by +35.05% over the past year.
The overall consensus recommendation for Galderma AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Galderma AG dividend yield is 0.15% based on the trailing twelve month period.
Last year, Galderma AG paid a total dividend of $0.17, and it currently has a trailing dividend yield of 0.15%.Looking ahead, the next dividend pay date is 2025-04-29.
We do not have data on when Galderma AG is to next pay dividends. The historic dividend yield on Galderma AG shares is currently 0.15%.
To buy shares in Galderma AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣90.00, shares in Galderma AG had a market capitalisation of CH₣21.37bn.
Here are the trading details for Galderma AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: GALD
Based on an overall assessment of its quality, value and momentum Galderma AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Galderma AG is CH₣108.68. That is 20.75% above the last closing price of CH₣90.00.
Analysts covering Galderma AG currently have a consensus Earnings Per Share (EPS) forecast of $2.73 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Galderma AG. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +14.87%.
As of the last closing price of CH₣90.00, shares in Galderma AG were trading +1.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Galderma AG PE ratio based on its reported earnings over the past 12 months is 34.87. The shares last closed at CH₣90.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Galderma AG's directors